A- A A+

Integrated care model and point of care diagnostics facilitate Hepatitis C treatment among patients receiving opioid agonist therapy: a retrospective review of medical records. 

Häkkinen, M., Tourunen, J., Pitkänen, T. et al.

Subst Abuse Treat Prev Policy 17, 44 (2022). doi.org/10.1186/s13011-022-00473-3

https://substanceabusepolicy.biomedcentral.com/articles/10.1186/s13011-022-00473-3

Setting foot in private spaces: extending the hepatitis C cascade of care to automatic needle/syringe dispensing machines, a mixed methods study. 

Coupland, H., Henderson, C., Pritchard-Jones, J. et al.

Harm Reduct J 19, 56 (2022). doi.org/10.1186/s12954-022-00640-6

https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-022-00640-6

Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort. 

Barré T, Carrat F, Ramier C, Fontaine H, Di Beo V, Bureau M, Dorival C, Larrey D, Delarocque-Astagneau E, Mathurin P, Marcellin F, Petrov-Sanchez V, Cagnot C, Carrieri P, Pol S, Protopopescu C; ANRS/AFEF Hepather study group. 

J Cannabis Res. 2022 Jun 11;4(1):31. doi: 10.1186/s42238-022-00138-9. PMID: 35690798; PMCID: PMC9188079.

https://pubmed.ncbi.nlm.nih.gov/35690798/

The hepatitis C epidemic in Canada: An overview of recent trends in surveillance, injection drug use, harm reduction and treatment. 

Lourenço L, Kelly M, Tarasuk J, Stairs K, Bryson M, Popovic N, Aho J. 

Can Commun Dis Rep. 2021 Dec 9;47(12):561-570. doi: 10.14745/ccdr.v47i12a01. PMID: 35692566; PMCID: PMC9126177.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126177/

Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression

Hosseini-Hooshyar, Samira et al.

The Lancet HIV, Volume 9, Issue 6, e414 - e427 

https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(22)00077-7/fulltext

Hepatitis C Virus Prevalence, Medical Status Awareness and Treatment Engagement among Homeless People Who use Drugs: Results of a Street Outreach Study. 

Lasmanovich R, Shaked O, Sivan A, Barak I, Nahari M, Mor O, Katchman H. 

Subst Abuse. 2022 May 26;16:11782218221095871. doi: 10.1177/11782218221095871. PMID: 35651594; PMCID: PMC9149611.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149611/

Establishing a framework towards monitoring HCV microelimination among men who have sex with men living with HIV in Germany: A modeling analysis. 

Marquez LK, Ingiliz P, Boesecke C, Krznaric I, Schewe K, Lutz T, Mauss S, Christensen S, Rockstroh JK, Jain S, He F, Wertheim JO, Martin NK. 

PLoS One. 2022 May 12;17(5):e0267853. doi: 10.1371/journal.pone.0267853. PMID: 35551326; PMCID: PMC9098082.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098082/

Impact of Co-occurring Drug Use, Hazardous Alcohol Use, and Mental Health Disorders on Drug Use Patterns in People With HIV and Hepatitis C Virus Infection. 

McCormick S, Ward KM, Sutcliffe CG, Irvin R, Chander G, Brooner RK, Mehta SH, Thomas DL, Sulkowski M, Falade-Nwulia O. 

Open Forum Infect Dis. 2021 Oct 19;8(11):ofab520. doi: 10.1093/ofid/ofab520. PMID: 35559126; PMCID: PMC9088503.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088503/

Case study of hepatitis C virus control in Egypt: impact of access program. 

Waked I. 

Antivir Ther. 2022 Apr;27(2):13596535211067592. doi: 10.1177/13596535211067592. PMID: 35491550.

https://journals.sagepub.com/doi/10.1177/13596535211067592

Hepatitis C prevalence and key population size estimate updates in San Francisco: 2015 to 2019. 

Facente SN, Grinstein R, Bruhn R, Kaidarova Z, Wilson E, Hecht J, Burk K, Grebe E, Morris MD.

PLoS One. 2022 May 11;17(5):e0267902. doi: 10.1371/journal.pone.0267902. PMID: 35544483; PMCID: PMC9094540.

https://pubmed.ncbi.nlm.nih.gov/35544483/

Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs. 

Yeung A, Palmateer NE, Dillon JF, McDonald SA, Smith S, Barclay S, Hayes PC, Gunson RN, Templeton K, Goldberg DJ, Hickman M, Hutchinson SJ. 

J Hepatol. 2022 Mar;76(3):549-557. doi: 10.1016/j.jhep.2021.09.038. Epub 2021 Oct 9. Erratum in: J Hepatol. 2022 May 9;: PMID: 34634387; PMCID: PMC8852744.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852744/

NRW. Richtungsweisendes Modellprojekt zur Behandlung von Hepatitis C im Justizvollzug in Nordrhein-Westfalen vorgestellt 

Projekt in der JVA Bochum unterstützt Ziel der Vereinten Nationen, Hepatitis C weltweit bis 2030 zu eliminieren. (Staatskanzlei des Landes Nordrhein-Westfalen, 19.05.2022)

https://www.land.nrw/pressemitteilung/richtungsweisendes-modellprojekt-zur-behandlung-von-hepatitis-c-im-justizvollzug

Simplifying HCV treatment: a pathway to elimination and model for delivering health care to vulnerable populations. 

Klein MB. 

Lancet Gastroenterol Hepatol. 2022 Apr;7(4):277-279. doi: 10.1016/S2468-1253(21)00467-2. Epub 2022 Jan 10. PMID: 35026143; PMCID: PMC8747435.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747435/

HCV Elimination in Central Europe with Particular Emphasis on Microelimination in Prisons. 

Flisiak R, Zarębska-Michaluk D, Ciupkeviciene E, Drazilova S, Frankova S, Grgurevic I, Hunyady B, Jarcuska P, Kupčinskas L, Makara M, Saulite-Vanaga G, Simonova M, Sperl J, Tolmane I, Vince A. 

Viruses. 2022 Feb 26;14(3):482. doi: 10.3390/v14030482. PMID: 35336889; PMCID: PMC8952509.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8952509/

Formal Hepatitis C Education Increases Willingness to Receive Therapy in an On-site Shelter-Based HCV Model of Care in Persons Experiencing Homelessness. 

Partida D, Powell J, Ricco M, Naugle J, Magee C, Zevin B, Masson CL, Konadu Fokuo J, Gonzalez D, Khalili M. 

Open Forum Infect Dis. 2022 Mar 1;9(4):ofac103. doi: 10.1093/ofid/ofac103. PMID: 35369281; PMCID: PMC8968162.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968162/

Real-life experience of hepatitis C treatment in a Spanish prison.

Tejera-Pérez RJ, Iglesias-Gómez A, Oliva-Oliva A, Rodríguez-Alonso B, Alonso-Sardón M, Sánchez Ledesma M, Carbonell-Muñoz C, Pendones Ulerio J, Muñoz-Bellido JL, Belhassen-García M. 

Rev Esp Quimioter. 2022 Apr 20:tejera20apr2022. doi: 10.37201/req/001.2022. Epub ahead of print. PMID: 35441836.

https://seq.es/abstract/rev-esp-quimioter-2022-april-20-3/

Elimination of HCV in Russia: Barriers and Perspective. 

Isakov V, Nikityuk D. 

Viruses. 2022 Apr 11;14(4):790. doi: 10.3390/v14040790. PMID: 35458520; PMCID: PMC9024583.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024583/

Factors associated with hepatitis C treatment adherence: an integrative review. 

Côco LT, Silva GF, Romeiro FG, Cerqueira ATAR. 

Cien Saude Colet. 2022 Apr;27(4):1359-1376. Portuguese, English. doi: 10.1590/1413-81232022274.06942021. Epub 2021 May 15. PMID: 35475818.

https://www.scielo.br/j/csc/a/nWWRxj9CX4bbmfhKcXCpd8d/?lang=en

Knowledge of hepatitis C and awareness of reinfection risk among people who successfully completed direct acting antiviral therapy. 

Yazdani K, Dolguikh K, Zhang W, Shayegi-Nik S, Ly J, Cooper S, et al. (2022) 

PLoS ONE 17(3): e0265811. doi.org/10.1371/journal.pone.0265811

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0265811

Hepatitis C diagnosis and treatment in people who use drugs: mind the gap in the linkage to care. 

Taibi C, Luzzitelli I, Visco Comandini U, Girardi E, Monacelli G, Rapisarda LM, Garbuglia AR, Minosse C, Guarrasi V, Vincenzi L, Iacomi F, D'Offizi G. 

Eur Rev Med Pharmacol Sci. 2021 Oct;25(19):5913-5921. doi: 10.26355/eurrev_202110_26867. PMID: 34661249.

https://www.europeanreview.org/article/26867

Modeling hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicago. 

Tatara E, Gutfraind A, Collier NT, Echevarria D, Cotler SJ, Major ME, et al. (2022) 

PLoS ONE 17(3): e0264983. doi.org/10.1371/journal.pone.0264983

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0264983

Effectiveness of Interventions for Prevention of Common Infections Among Opioid Users: A Systematic Review of Systematic Reviews. 

Puzhko S, Eisenberg MJ, Filion KB, Windle SB, Hébert-Losier A, Gore G, Paraskevopoulos E, Martel MO, Kudrina I. 

Front Public Health. 2022 Feb 22;10:749033. doi: 10.3389/fpubh.2022.749033. PMID: 35273933; PMCID: PMC8901608.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901608/

Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users. 

Hsu JT, Hsu PI, Shie CB, Chuah SK, Wu IT, Huang WW, Tang SY, Tsai KF, Kuo LF, Ghose S, Hsu JC, Shih CA. 

Medicina (Kaunas). 2022 Mar 17;58(3):436. doi: 10.3390/medicina58030436. PMID: 35334612; PMCID: PMC8950806.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950806/

Hepatitis C: Standard of Treatment and What to Do for Global Elimination. 

Di Marco L, La Mantia C, Di Marco V. 

Viruses. 2022 Feb 28;14(3):505. doi: 10.3390/v14030505. PMID: 35336911; PMCID: PMC8954407.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954407/

The Importance of Prisons in Achieving Hepatitis C Elimination: Insights from the Australian Experience. 

Winter RJ, Holmes JA, Papaluca TJ, Thompson AJ. 

Viruses. 2022 Feb 28;14(3):497. doi: 10.3390/v14030497. PMID: 35336905; PMCID: PMC8949789.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949789/

Barriers of linkage to HCV viremia testing among people who inject drugs in Georgia. 

Butsashvili M, Abzianidze T, Kamkamidze G, Gulbiani L, Gvinjilia L, Kuchuloria T, Tskhomelidze I, Gogia M, Tsereteli M, Miollany V, Kikvidze T, Shadaker S, Nasrullah M, Averhoff F. 

Subst Abuse Treat Prev Policy. 2022 Mar 28;17(1):23. doi: 10.1186/s13011-022-00438-6. PMID: 35346265; PMCID: PMC8962019.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962019/

Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada. 

Lanièce Delaunay C, Maheu-Giroux M, Marathe G, Saeed S, Martel-Laferrière V, Cooper CL, Walmsley S, Cox J, Wong A, Klein MB; Canadian Coinfection Cohort investigators.

Int J Drug Policy. 2022 Feb 23;103:103627. doi: 10.1016/j.drugpo.2022.103627. Epub ahead of print. PMID: 35218989.

https://www.sciencedirect.com/science/article/pii/S0955395922000470

Strategietreffen Virushepatitis 2022 Aktuelles Positionspapier im Kampf gegen Hepatitis B und C

Gegen Hepatitis C gibt es hochwirksame Therapien – nun soll es mit Aufklärung, Prävention und Früherkennung auch gelingen, sie zu den Betroffenen zu bringen und die Virushepatitis bis 2030 in Deutschland zu eliminieren. Auf entsprechende Maßnahmen haben sich Experten aus Medizin, Wissenschaft, Politik und Versorgungspraxis am letzten Mittwoch im Rahmen des 'Strategietreffens Virushepatitis' verständigt. Auf der virtuellen Veranstaltung, die die Deutsche Leberstiftung in Kooperation mit der Hepatitis B & C Public Policy Association durchführte, wurden im breiten Konsens ein Positionspapier verabschiedet, das die Elimination der tückischen Erkrankungen vorantreiben soll. (Deutsche Leberstiftung, 16.02.2022)

https://idw-online.de/de/news788541

Exploring hepatitis C virus testing and treatment engagement over time in Melbourne, Australia: a study protocol for a longitudinal cohort study (EC-Experience Cohort study). 

O'Keefe D, Gunn J, Ryan K, Djordjevic F, Kerr P, Gold J, Elsum I, Layton C, Chan K, Dietze P, Higgs P, Doyle J, Stoové MA, Hellard M, Pedrana AE. 

BMJ Open. 2022 Jan 4;12(1):e057618. doi: 10.1136/bmjopen-2021-057618. PMID: 34983773; PMCID: PMC8728403.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728403/

The contribution of unstable housing to HIV and hepatitis C virus transmission among people who inject drugs globally, regionally, and at country level: a modelling study

Stone, Jack et al.

The Lancet Public Health, Volume 7, Issue 2, e136 - e145 

https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(21)00258-9/fulltext